NCT02532413

Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B

Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate antiviral efficacy of the combination treatment with Poly IC and Entecavir and compare with the efficacy of Entecavir mono-therapy for chronic hepatitis B.

Detailed description

In this study, the patients with chronic HBV infection will be divided into two groups: HBeAg (+) and HBeAg (-) group. Each group will be divided into two subgroups, which are treated with combination treatment of Entecavir and Poly IC and Entecavir monotherapy respectively. All the patients will be followed up for one year. From this study, the investigators want to study if Poly IC can enhance antiviral efficacy of Entecavir for chronic hepatitis B.

Conditions

• Chronic Hepatitis B

Interventions

Type	Name	Description
DRUG	Poly IC	Poly IC can induce innate immune responses.It may enhance the antiviral efficacy of Entecavir.
DRUG	Entecavir	Entecavir can inhibit the replication of HBV.

Timeline

• Start date: 2015-07-01
• Primary completion: 2016-08-01
• Completion: 2017-08-01
• First posted: 2015-08-25
• Last updated: 2015-08-25

Locations

1 site across 1 country: China